Core Viewpoint - The company, Langkun Technology, has made significant progress in its HMO (Human Milk Oligosaccharides) project, which is now in the trial production phase, marking a substantial breakthrough in synthetic biology manufacturing [1] Group 1: HMO Project Development - The company's wholly-owned subsidiary, Langjian Biotechnology, has entered trial production for its first phase of HMO with an annual production capacity of 260 tons [1] - The second phase, with an expected annual capacity of 740 tons, is projected to commence production in 2026, bringing total capacity to 1,000 tons per year [1] - Langkun Technology has become the first domestic company approved for LNnT (Lactose-N-Tetraose) as a food additive, indicating a potential to disrupt the market dominated by foreign companies [1] - The future applications of HMOs extend beyond infant formula to health supplements and functional foods, suggesting a higher market ceiling [1] - The success of the HMO project validates the company's capability in producing high-end products using synthetic biology technology, which can be applied to develop other high-value products [1] Group 2: Traditional Business and Market Impact - The company's traditional business focuses on the harmless treatment and resource utilization of organic solid waste, including food waste and urban household waste [2] - The upcoming National Day and Mid-Autumn Festival holidays are expected to increase the volume of restaurant and household waste, positively impacting the company's short-term revenue [2] - Despite a 4.31% year-on-year decline in main revenue to 855 million yuan in the first half of 2025, the company reported a 22.36% increase in net profit attributable to shareholders, indicating strong profitability [1]